Abstract
Testicular cancer is a rare tumor, subdivided into seminomatous and nonseminomatous tumors. Whereas there are no serum tumor markers in the first group, they are present in nonseminomatous tumors, and are also important prognostic factors. Overall, the prognosis for testicular cancers is good, which makes the choice of accurate treatment intensity between under- and overtreatment often difficult. Residual masses in advanced clinical stages occur frequently but are nonvital tissue. PET with F-18 FDG has no defined role in imaging of primary tumors where CT is the first-choice imaging modality. For assessing the success of chemotherapy in the presence of residual masses, especially in pure seminoma, F-18 FDG PET is an important tool. In nonseminomatous tumors, it is hampered by the false-negative results in mature teratoma, for which reason false-negative results are a common problem. F-18 FDG PET performs best in predicting relapse in seminoma residuals larger than 3 cm. So far, no alternative to F-18 FDG for PET imaging of testicular cancer has been found. PET-CT has not yet been proven to be superior to PET alone in testicular cancer.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Hoei-Hansen, C.E., Rajpert-De Meyts, E., Daugaard, G., Skakkebaek, N.E. (2005) Carcinoma in situ testis, the progenitor of testicular germ cell tumours: a clinical review Ann Oncol 16(6), 863–8.
Dieckmann, K.P., Loy, V. (1996) Prevalence of contralateral testicular intraepithelial neoplasia in patients with testicular germ cell neoplasms J Clin Oncol 14(12), 3126–32.
Harland, S.J., Cook, P.A., Fossa, S.D., et al. (1998) Intratubular germ cell neoplasia of the contralateral testis in testicular cancer: defining a high risk group J Urol 160(4), 1353–7.
Warde, P., Specht, L., Horwich, A., et al. (2002) Prognostic factors for relapse in stage I seminoma managed by surveillance: a pooled analysis J Clin Oncol 20(22), 4448–52.
Albers, P., Siener, R., Hartmann, M., et al. (1999) Risk factors for relapse in stage I non-seminomatous germ-cell tumors: preliminary results of the German Multicenter Trial. German Testicular Cancer Study Group Int J Cancer 83(6), 828–30.
Lindholm, P., Minn, H., Leskinen-Kallio, S., Bergman, J., Ruotsalainen, U., Joensuu, H. (1993). Influence of the blood glucose concentration on FDG uptake in cancer – a PET study J Nucl Med. 34(1), 1–6.
White, P.M., Adamson, D.J., Howard, G.C., Wright, A.R. (1999) Imaging of the thorax in the management of germ cell testicular tumours Clin Radiol 54(4), 207–11.
Krege, S., Beyer, J., Souchon, R., et al. (2008) European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I Eur Urol 53(3), 478–96.
Sternberg, C.N. (1998) The management of stage I testis cancer Urol Clin North Am 25(3), 435–49.
Krug, B., Heidenreich, A., Dietlein, M., Lackner, K. (1999) The lymph node staging of malignant testicular germ-cell tumors Rofo 171(2), 87–94.
Rustin, G.J., Mead, G.M., Stenning, S.P., et al. (2007) Randomized trial of two or five computed tomography scans in the surveillance of patients with stage I nonseminomatous germ cell tumors of the testis: Medical Research Council Trial TE08, ISRCTN56475197 – the National Cancer Research Institute Testis Cancer Clinical Studies Group J Clin Oncol 25(11), 1310–5.
Klepp, O., Dahl, O., Flodgren, P., et al. (1997) Risk-adapted treatment of clinical stage 1 non-seminoma testis cancer Eur J Cancer 33(7), 1038–44.
Albers, P., Bender, H., Yilmaz, H., Schoeneich, G., Biersack, H.J., Mueller, S.C. (1999) Positron emission tomography in the clinical staging of patients with Stage I and II testicular germ cell tumors Urology 53(4), 808–11.
Bender, H., Schomburg, A., Albers, P., Ruhlmann, J., Biersack, H.J. (1997) Possible role of FDG-PET in the evaluation of urologic malignancies Anticancer Res 17(3B), 1655–60.
de Wit, M., Brenner, W., Hartmann, M., et al. (2008) [18F]-FDG-PET in clinical stage I/II non-seminomatous germ cell tumours: results of the German multicentre trial Ann Oncol 19(9), 1619–23.
Huddart, R.A., O’Doherty, M.J., Padhani, A., et al. (2007) 18-fluorodeoxyglucose positron emission tomography in the prediction of relapse in patients with high-risk, clinical stage I nonseminomatous germ cell tumors: preliminary report of MRC Trial TE22 – the NCRI Testis Tumour Clinical Study Group J Clin Oncol 25(21), 3090–5.
Oliver, R.T., Mason, M.D., Mead, G.M., et al. (2005) Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trial Lancet 366(9482), 293–300.
Spermon, J.R., De Geus-Oei, L.F., Kiemeney, L.A., Witjes, J.A., Oyen, W.J. (2002) The role of (18)fluoro-2-deoxyglucose positron emission tomography in initial staging and re-staging after chemotherapy for testicular germ cell tumours BJU Int 89(6), 549–56.
Lassen, U., Daugaard, G., Eigtved, A., Hojgaard, L., Damgaard, K., Rorth, M. (2003) Whole-body FDG-PET in patients with stage I non-seminomatous germ cell tumours Eur J Nucl Med Mol Imaging 30(3), 396–402.
Muller-Mattheis, V., Reinhardt, M., Gerharz, C.D., et al. (1998) Positron emission tomography with [18 F]-2-fluoro-2-deoxy-D-glucose (18FDG-PET) in diagnosis of retroperitoneal lymph node metastases of testicular tumors Urologe A 37(6), 609–20.
Reinhardt, M.J., Muller-Mattheis, V.G., Gerharz, C.D., Vosberg, H.R., Ackermann, R., Muller-Gartner, H.W. (1997) FDG-PET evaluation of retroperitoneal metastases of testicular cancer before and after chemotherapy J Nucl Med 38(1), 99–101.
Cremerius, U., Effert, P.J., Adam, G., et al. (1998) FDG PET for detection and therapy control of metastatic germ cell tumor J Nucl Med 39(5), 815–22.
Quek, M.L., Simma-Chiang, V., Stein, J.P., Pinski, J., Quinn, D.I., Skinner, D.G. (2005) Postchemotherapy residual masses in advanced seminoma: current management and outcomes Expert Rev Anticancer Ther 5(5), 869–74.
Puc, H.S., Heelan, R., Mazumdar, M., et al. (1996) Management of residual mass in advanced seminoma: results and recommendations from the Memorial Sloan-Kettering Cancer Center J Clin Oncol 14(2), 454–60.
Horwich, A., Paluchowska, B., Norman, A., et al. (1997) Residual mass following chemotherapy of seminoma Ann Oncol 8(1), 37–40.
Motzer, R., Bosl, G., Heelan, R., et al. (1987) Residual mass: an indication for further therapy in patients with advanced seminoma following systemic chemotherapy J Clin Oncol 5(7), 1064–70.
Mosharafa, A.A., Foster, R.S., Koch, M.O., Bihrle, R., Donohue, J.P. (2004) Complications of post-chemotherapy retroperitoneal lymph node dissection for testis cancer J Urol 171(5), 1839–41.
Bokemeyer, C., Kollmannsberger, C., Oechsle, K., et al. (2002) Early prediction of treatment response to high-dose salvage chemotherapy in patients with relapsed germ cell cancer using [(18)F]FDG PET Br J Cancer 86(4), 506–11.
De Santis, M., Bokemeyer, C., Becherer, A., et al. (2001) Predictive impact of 2-18fluoro-2-deoxy-D-glucose positron emission tomography for residual postchemotherapy masses in patients with bulky seminoma J Clin Oncol 19(17), 3740–4.
De Santis, M., Becherer, A., Bokemeyer, C., et al. (2004) 2-18fluoro-deoxy-d-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial J Clin Oncol 22(6), 1034–9.
Becherer, A., De Santis, M., Karanikas, G., et al. (2005) FDG PET is superior to CT in the prediction of viable tumour in post-chemotherapy seminoma residuals Eur J Radiol 54(2), 284–8.
Krege, S., Beyer, J., Souchon, R., et al. (2008) European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part II Eur Urol 53(3), 497–513.
Ganjoo, K.N., Chan, R.J., Sharma, M., Einhorn, L.H. (1999) Positron emission tomography scans in the evaluation of postchemotherapy residual masses in patients with seminoma J Clin Oncol17:3457–60.
Guido, A., Fuccio, L., Rombi, B., et al. (2008) Combined (18)F FDG-PET/CT imaging in radiotherapy target delineation for head-and-neck cancer Int J Radiat Oncol Biol Phys 73(3), 759–63.
Deantonio, L., Beldi, D., Gambaro, G., et al. (2008) FDG-PET/CT imaging for staging and radiotherapy treatment planning of head and neck carcinoma Radiat Oncol 3, 29.
Newbold, K.L., Partridge, M., Cook, G., et al. (2008) Evaluation of the role of 18FDG-PET/CT in radiotherapy target definition in patients with head and neck cancer Acta Oncol 47(7), 1229–36.
Yu, H.M., Liu, Y.F., Hou, M., Liu, J., Li, X.N., Yu, J.M. (2008) Evaluation of gross tumor size using CT, (18)F-FDG PET, integrated (18)F-FDG PET/CT and pathological analysis in non-small cell lung cancer Eur J Radiol 72(1), 104–13.
Sugawara, Y., Zasadny, K.R., Grossman, H.B., Francis, I.R., Clarke, M.F., Wahl, R.L. (1999) Germ cell tumor: differentiation of viable tumor, mature teratoma, and necrotic tissue with FDG PET and kinetic modeling Radiology 211(1), 249–56.
Rayson, D., Burch, P.A., Richardson, R.L. (1998) Sarcoidosis and testicular carcinoma Cancer 83(2), 337–43.
Karapetis, C.S., Strickland, A.H., Yip, D., van der Walt, J.D., Harper, P.G. (2001) PET and PLAP in suspected testicular cancer relapse: beware sarcoidosis Ann Oncol 12(10), 1485–8.
Muggia, F.M., Conti, P.S. (1998) Seminoma and sarcoidosis: a cause for false positive mediastinal uptake in PET Ann Oncol 9(8), 924.
Waterston, A., Seywright, M., White, J. (2006) A salutary tale of mistaken identity in testicular cancer Urol Oncol 24(5), 407–9.
Wang, J., Cook, G., Frank, J., et al. (2007) Case report: PET/CT, a cautionary tale BMC Cancer 7, 147.
Nakamura, H., Makino, K., Kuratsu, J.I. (2009) Carbon 11-labeled methionine positron emission tomography for detection of residual viable tumor cells after adjuvant therapy in nongerminomatous malignant germ cell tumors in 2 cases including an autopsy case Surg Neurol 71(1), 83–8.
Kole, A.C., Hoekstra, H.J., Sleijfer, D.T., Nieweg, O.E., Schraffordt Koops, H., Vaalburg, W. (1998) L-[1-carbon-11]tyrosine imaging of metastatic testicular nonseminoma germ-cell tumors J Nucl Med 39(6), 1027–9.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Humana Press
About this protocol
Cite this protocol
Becherer, A. (2011). PET in Testicular Cancer. In: Juweid, M., Hoekstra, O. (eds) Positron Emission Tomography. Methods in Molecular Biology, vol 727. Humana Press. https://doi.org/10.1007/978-1-61779-062-1_13
Download citation
DOI: https://doi.org/10.1007/978-1-61779-062-1_13
Published:
Publisher Name: Humana Press
Print ISBN: 978-1-61779-061-4
Online ISBN: 978-1-61779-062-1
eBook Packages: Springer Protocols